Prosecution Insights
Last updated: April 19, 2026
Application No. 17/713,110

Methods and Apparatuses for Assessment and Management of Hemodynamic Status

Final Rejection §112
Filed
Apr 04, 2022
Examiner
YOON, CHANEL J
Art Unit
3791
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Medici Technologies LLC
OA Round
3 (Final)
52%
Grant Probability
Moderate
4-5
OA Rounds
3y 5m
To Grant
90%
With Interview

Examiner Intelligence

Grants 52% of resolved cases
52%
Career Allow Rate
98 granted / 187 resolved
-17.6% vs TC avg
Strong +38% interview lift
Without
With
+38.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
63 currently pending
Career history
250
Total Applications
across all art units

Statute-Specific Performance

§101
17.3%
-22.7% vs TC avg
§103
34.5%
-5.5% vs TC avg
§102
14.3%
-25.7% vs TC avg
§112
29.1%
-10.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 187 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Amendment Entered In response to the amendment filed on November 6th, 2025, amended claims 1-2 and 6 and new claim 14 are entered. Claims 8-10 remain withdrawn. Claims 1-7 and 11-14 are currently being considered for examination. Response to Arguments Applicant's remarks and amendments with respect to the rejections under 35 U.S.C. 101 have been fully considered. The rejections are withdrawn in view of the amendment. Applicant's remarks and amendments with respect to the rejections under 35 U.S.C. 103 have been fully considered. The rejections are withdrawn in view of the amendment. Claim Objection Claim 13 is objected to because of the following informality: Claim 13 recites “the variation of time intervals” in line 1, but should read “the variation of the two or more systolic time intervals” Appropriate correction is required. Claim Interpretation The following is a quotation of 35 U.S.C. 112(f): (f) Element in Claim for a Combination. – An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof. The following is a quotation of pre-AIA 35 U.S.C. 112, sixth paragraph: An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof. The claims in this application are given their broadest reasonable interpretation using the plain meaning of the claim language in light of the specification as it would be understood by one of ordinary skill in the art. The broadest reasonable interpretation of a claim element (also commonly referred to as a claim limitation) is limited by the description in the specification when 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is invoked. As explained in MPEP § 2181, subsection I, claim limitations that meet the following three-prong test will be interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph: (A) the claim limitation uses the term “means” or “step” or a term used as a substitute for “means” that is a generic placeholder (also called a nonce term or a non-structural term having no specific structural meaning) for performing the claimed function; (B) the term “means” or “step” or the generic placeholder is modified by functional language, typically, but not always linked by the transition word “for” (e.g., “means for”) or another linking word or phrase, such as “configured to” or “so that”; and (C) the term “means” or “step” or the generic placeholder is not modified by sufficient structure, material, or acts for performing the claimed function. Use of the word “means” (or “step”) in a claim with functional language creates a rebuttable presumption that the claim limitation is to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites sufficient structure, material, or acts to entirely perform the recited function. Absence of the word “means” (or “step”) in a claim creates a rebuttable presumption that the claim limitation is not to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is not interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites function without reciting sufficient structure, material or acts to entirely perform the recited function. Claim limitations in this application that use the word “means” (or “step”) are being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. Conversely, claim limitations in this application that do not use the word “means” (or “step”) are not being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. This application includes one or more claim limitations that do not use the word “means,” but are nonetheless being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, because the claim limitation(s) uses a generic placeholder that is coupled with functional language without reciting sufficient structure to perform the recited function and the generic placeholder is not preceded by a structural modifier. Such claim limitation(s) is/are: “volume status determination system” in claim 1 “communication device” in claim 3 Because this/these claim limitation(s) is/are being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, it/they is/are being interpreted to cover the corresponding structure described in the specification as performing the claimed function, and equivalents thereof. If applicant does not intend to have this/these limitation(s) interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, applicant may: (1) amend the claim limitation(s) to avoid it/them being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph (e.g., by reciting sufficient structure to perform the claimed function); or (2) present a sufficient showing that the claim limitation(s) recite(s) sufficient structure to perform the claimed function so as to avoid it/them being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-7 and 11-14 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 recites “by allowing air flow during inhalation or exhalation, or both, by the patient after the patient's inhalation or exhalation, or both, provides a pressure that exceeds a pressure threshold” in lines 5-7. It is unclear as to what this limitation exactly entails as there seems to be a missing word or a grammatical error present. Currently, it is unclear as to how the air flow can be allowed during inhalation or exhalation, or both by the patient after the patient's inhalation or exhalation, or both, provides a pressure that exceeds a pressure threshold. Assuming that “the patient's inhalation or exhalation, or both” recited in line 6 is referring to the same “inhalation or exhalation, or both, by the patient” recited earlier in line 6, it seems contradictory that the device can allow air flow during a breath based on a condition that occurs afterwards. Clarification is requested. Furthermore, it is unclear as to what “both” exactly means in the context of these limitations. If the term “both” is meant to include both inhalation and exhalation, the claim would be understood as “by allowing air flow during both inhalation and exhalation, by the patient after both the patient's inhalation and exhalation provides a pressure that exceeds a pressure threshold”. It is unclear as to how these conditions could be met simultaneously to allow air flow during both inhalation and exhalation, as inhalation and exhalation can only happen at separate times. Furthermore, if the conditions are not meant to be met simultaneously, it is unclear as to whether there is a chronological order that must be met instead. Clarification is requested. Claim 1 recites the limitation “the airway resistance devices” in lines 8-9. There is insufficient antecedent basis for this limitation in the claim. Examiner notes that this limitation is in a plural form. Therefore, it is unclear as to whether this limitation is supposed to be referring to the singular “airway resistance device” previously introduced in line 4, or supposed to be referring to a separate element of a plural group of “airway resistance devices”. Claim 1 recites the limitation “repeatable intrathoracic pressure perturbations” in line 10. Examiner notes that this limitation is in a plural form. Therefore, it is unclear as to whether this limitation is supposed to be referring to the singular “repeatable intrathoracic pressure perturbation” previously introduced in line 5, or supposed to be referring to a separate element of a plural group of “repeatable intrathoracic pressure perturbations”. Claim 2 recites “a variation of the two or more systolic time intervals measured during the presence of air flow” in line 3. It is unclear as to whether this limitation is referring to the previously introduced “a variation of the two or more systolic time intervals” from Claim 1, or a separate element. Examiner notes that since the “two or more systolic time intervals” of Claim 1 were obtained during the repeatable intrathoracic pressure perturbations, there would also be a presence of air flow then. Claim 6 recites “the pulse contours” in line 3. It is unclear as to whether this limitation is referring to the previously introduced “pulse contours” from line 2 of Claim 1, “one or more pulse contours obtained from the patient during repeatable intrathoracic pressure perturbations” in lines 9-10 of Claim 1, or a separate element. Claim 14 recites “at least one flow-independent pressure valve” in lines 1-2. It is unclear as to whether this limitation is referring to the previously introduced “at least one flow-independent pressure valve” from line 4 of Claim 1, or a separate element. Claim 14 recites “a repeatable intrathoracic pressure perturbation” in lines 2-3. It is unclear as to whether this limitation is referring to the previously introduced “repeatable intrathoracic pressure perturbation” from line 5 of Claim 1, or a separate element. Claim 14 recites “exhalation by the patient” in line 3. It is unclear as to whether this limitation is referring to the previously introduced “exhalation…by the patient” from line 6 of Claim 1, or a separate element. Claim 14 recites “a pressure” in line 4. It is unclear as to whether this limitation is referring to the previously introduced “pressure” from line 7 of Claim 1, or a separate element. Claim 14 recites “a pressure threshold” in line 4. It is unclear as to whether this limitation is referring to the previously introduced “pressure threshold” from line 7 of Claim 1, or a separate element. Furthermore, Claim 14 recites “wherein the airway resistance device comprises at least one flow-independent pressure valve configured to generate in the patient a repeatable intrathoracic pressure perturbation by allowing air flow during exhalation by the patient after exhalation by the patient provides a pressure that exceeds a pressure threshold” in lines 1-4. It is unclear as to what this limitation exactly entails as there seems to be a missing word or a grammatical error present. Currently, it is unclear as to how the air flow can be allowed during exhalation after exhalation by the patient provides a pressure that exceeds a pressure threshold. Assuming that the second recitation of the “exhalation by the patient” recited in line 3 of Claim 14 is referring to the same “exhalation by the patient” recited earlier in line 3, it seems contradictory that the device can allow air flow during a breath based on a condition that occurs afterwards. Clarification is requested. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHANEL J YOON whose telephone number is (571) 272-2695. The examiner can normally be reached on Monday-Friday 9:00AM-5:00PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Alexander Valvis can be reached on 571-272-4233. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see https://ppair-my.uspto.gov/pair/PrivatePair. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CHANEL J YOON/Examiner, Art Unit 3791 /ALEX M VALVIS/Supervisory Patent Examiner, Art Unit 3791
Read full office action

Prosecution Timeline

Apr 04, 2022
Application Filed
Jun 09, 2022
Response after Non-Final Action
Nov 01, 2024
Non-Final Rejection — §112
May 01, 2025
Response Filed
Jun 04, 2025
Non-Final Rejection — §112
Nov 06, 2025
Response Filed
Feb 19, 2026
Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12582321
CARDIAC DIASTOLIC FUNCTION ASSESSMENT METHOD, DEVICE, AND SYSTEM
2y 5m to grant Granted Mar 24, 2026
Patent 12533069
Systems and Methods of Electrode Switching for Neurophysiological Sensing and Stimulation
2y 5m to grant Granted Jan 27, 2026
Patent 12521037
APPARATUS, SYSTEM, AND METHOD FOR DETECTING PHYSIOLOGICAL MOVEMENT FROM AUDIO AND MULTIMODAL SIGNALS
2y 5m to grant Granted Jan 13, 2026
Patent 12502112
SYSTEMS AND METHODS FOR EVALUATING ORAL FUNCTION
2y 5m to grant Granted Dec 23, 2025
Patent 12484798
ASSESSMENT OF SKIN PERFUSION USING MICROWAVE HEATING AND USING INFRARED RADIOMETRY
2y 5m to grant Granted Dec 02, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

4-5
Expected OA Rounds
52%
Grant Probability
90%
With Interview (+38.1%)
3y 5m
Median Time to Grant
High
PTA Risk
Based on 187 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month